Analysis of the near full length genomes of HIV-1 subtypes B, F and BF recombinant from a cohort of 14 patients in São Paulo, Brazil

Sanabani, Sabri Saeed; Neto, Walter Kleine; Kalmar, E.; Diaz, Ricardo Sobhie; Janini, Luiz Mário; Sabino, Éster Cerdeira

doi:10.1016/j.meegid.2006.01.003

Cited by 49 publications

(69 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it shall be pointed out that the numbers from the exported plasma are closer to the international experience and provides a NAT HIV yield thirteen times smaller than the estimate of BARRETO et al 2 and AMORIM et al 1 (1:33,333), as illustrated in Table 6. In the US, a recent compilation of the data 16 shows a yield of NAT isolated HIV reactive donations of 1:3,100,000, which is three times lower than previous estimates (1:1,000,000) 14 .…”

Section: Discussionmentioning

confidence: 65%

See 1 more Smart Citation

Replacement of HIV p24 Ag test by a multiplex RT-PCR method for primary screening of blood donors

Levi

Wendel

Takaoka³

et al. 2007

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

SUMMARYNucleic Acid Testing (NAT) as a tool for primary screening of blood donors became a reality in the end of the 1990 decade. We report here the development of an "in-house" RT-PCR method that allows the simultaneous (multiplex) detection of HCV and HIV-RNA in addition to an artificial RNA employed as an external control. This method detects all HIV group M subtypes, plus group N and O, with a detection threshold of 500 IU/mL. After validation, the method replaced p24 Ag testing, in use for blood donation screening since 1996 at our services. From July 2001 to February 2006, 102,469 donations were tested and 41 (0.04%) were found HIV-RNA reactive. One NAT-only reactive donation (antibody non-reactive) was observed, with subsequent seroconversion of the implied donor, giving a yield of 1:102,469. This rate is in contrast to the international experience that reports a detection of approximately 1:600,000 -1:3,100,000 of isolated HIV-RNA donations.

show abstract

Section: Discussionmentioning

confidence: 65%

“…Phylogenetic analysis, available through the Brazilian HIV Genotyping Algorithm site (http:// www.aids.gov.br/genotipagem) classified this isolate as a circulating recombinant form B/F1, which is commonly found in HIV-infected persons in São Paulo city 14 .…”

Section: D) Seroconversion Samplesmentioning

confidence: 99%

Replacement of HIV p24 Ag test by a multiplex RT-PCR method for primary screening of blood donors

Levi

Wendel

Takaoka³

et al. 2007

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…6 The presence of these recombinants and related unique mosaic strains increased over the years, favored by the high number of injecting drug users, sexual contacts, and the cocirculation of subtype B, F, and BF viruses in the same populations. 7,8 Afterward, BF mosaics were described in other Southern America countries 9,10 as well as in European countries such as Spain 13 and Luxembourg (where CRF42_BF has been isolated). Recently, a full-length sequence of a BF recombinant strain with a unique mosaic pattern has been characterized in Italy 14 in a patient with multiple risk factors and found to be phylogenetically related to two other sequences from Brazil.…”

Section: Aids Research and Human Retrovirusesmentioning

confidence: 99%

“…In addition, other sequences showed BF1 mosaics within the individual pol or env region. Since BF recombinants have been previously reported in Latin America, [5][6][7][8][9][10][11] we were interested in analyzing BF mosaic forms circulating in Italy.…”

mentioning

confidence: 99%

Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy

Saladini

Foley

Rosi

et al. 2012

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Recombination between HIV-1 subtypes B and F has generated several circulating and unique recombinant forms, particularly in Latin American areas. In Italy, subtype B is highly prevalent while subtype F is the most common pure non-B subtype. To investigate the recombination pattern in Italian BF recombinant viruses, we characterized full-length sequences derived from 15 adult patients, mostly Italian and infected by the heterosexual route. One of the BF mosaics was a CRF29, three sequences clustered with low bootstrap values with CRF39, CRF40, and CRF42. With the exception of the CRF29-like sequence, the other recombination patterns were unique, but two possible clusters were identified. Analysis of the gp120 V3 domain suggested a possible link with subtype F from Eastern Europe rather than from Latin America, favoring the hypothesis of local recombination between clade B and F viruses over that of import of BF recombinants from Latin America. HIV-1 subtypes B and F appear prone to generation of unique recombinants in Italy, warranting epidemiological surveillance and investigation of a possible clinical significance.H uman immunodeficiency virus type 1 (HIV-1) is characterized by an extremely broad genetic diversity, caused by high mutation and recombination rates. Currently, HIV-1 group M (''Major''), which is responsible of the worldwide pandemic, is divided into pure subtypes A-D, F-H, J, and K (with subtypes A and F further subdivided into subsubtypes A1-A4 and F1-F2, respectively) as well as 48 circulating recombinant forms (CRFs) of varying epidemiological significance, and untold numbers of unique recombinants that are not known to have spread to many patients. Subtype B has long been predominant in Western European countries but the prevalence of non-B strains has been increasing significantly in past years as a consequence of recent migration waves from Africa, Eastern Europe, and South America.1 Continuous surveillance of HIV-1 molecular epidemiology plays a critical role in the understanding of genetic diversity of HIV-1 and for research purposes such as vaccine development. In clinical practice, pol-based subtype assignment is usually accomplished as a by-product of genotypic antiretroviral resistance testing.A homebrew HIV-1 genotyping assay has been established and offered as a public health service at the HIV Monitoring Laboratory (HML), Department of Molecular Biology, University of Siena, Italy since 1995. 2 The laboratory has been serving a number of clinics for analysis of drug resistance mutations accumulating around 10,000 protease and reverse transcriptase sequences from more than 4000 patients. In addition, some hundred partial gag and env sequences have been obtained for research studies. A recent survey on the whole HIV-1 sequence database at the HML revealed 85% of subtype B sequences and 15% of non-B subtypes, mainly CRF02_AG, F1, C, and A1, based on the pol region.3 In some cases, assignments of subtype based on the pol and env regions were not in agreement. 4 These discrepan...

show abstract

“…Na América do Sul, apesar do subtipo B ainda ser o de maior prevalência, a freqüência do F e do C, bem como de formas recombinantes (BF, BC, FC) têm aumentado significativamente (Leal et al, 2008;Sanabani et al, 2006). O subtipo F e recombinantes BF têm sido frequentemente encontrados em muitos países sul americanos (Carr et al, 2001).…”

Section: Até O Momento Foram Evidenciados Por Estudos Sorológicos Dounclassified

Evolução das mutações de resistência aos inibidores de protease em pacientes infectados pelo HIV-1 subtipo F

Oliveros¹

View full text Add to dashboard Cite

Analysis of the near full length genomes of HIV-1 subtypes B, F and BF recombinant from a cohort of 14 patients in São Paulo, Brazil

Cited by 49 publications

References 19 publications

Replacement of HIV p24 Ag test by a multiplex RT-PCR method for primary screening of blood donors

Replacement of HIV p24 Ag test by a multiplex RT-PCR method for primary screening of blood donors

Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy

Evolução das mutações de resistência aos inibidores de protease em pacientes infectados pelo HIV-1 subtipo F

Contact Info

Product

Resources

About